Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 10/20 | 0.44 |
| ▸ | ITK | Q08881 | 10/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20319065 | 0.87 | AXL (0.45) | SGK1BTKITKMETCLK1 | |
| SCHEMBL31403510 | 0.84 | AXL (0.48) | SGK1BTKITK | |
| SCHEMBL30731143 | 0.82 | SGK1 (0.45) | SGK1CLK1DYRK1ADYRK1BRIPK1 | |
| SCHEMBL22554203 | 0.82 | SGK1 (0.45) | SGK1CLK1DYRK1ADYRK1BRIPK1 | |
| SCHEMBL7921128 | 0.74 | MET (0.46) | BTKITKMETMAP3K12PRMT5 | |
| SCHEMBL17982075 | 0.73 | CLK1 (0.55) | BTKITKCLK1DYRK1ADYRK1B | |
| SCHEMBL21417364 | 0.73 | BTK (0.36) | BTKITKMETMAP3K12ABL1 | |
| SCHEMBL18369564 | 0.72 | MET (0.45) | SGK1BTKITKMETMAP3K12 | |
| SCHEMBL10269012 | 0.72 | MET (0.43) | BTKITKMETCLK1DYRK1A | |
| SCHEMBL1566306 | 0.72 | ITK (0.54) | BTKITKMETDYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | API5, CDK5, MAPKAPK5 | SGK1 324/4885BTK 1875/4885ITK 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.